Hirtle Callaghan & Co’s Novo Nordisk NVO Stock Holding History

Hirtle Callaghan & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,457	Closed	-$715K	–	131
2026 Q1	$715K	Hold	19,457	–	–	0.02%	72
2025 Q4	$990K	Hold	19,457	–	–	0.03%	66
2025 Q3	$1.08M	Hold	19,457	–	–	0.04%	60
2025 Q2	$1.34M	Buy	19,457 +896	+5%	+$60.9K	0.05%	57
2025 Q1	$1.29M	Buy	+18,561	New	+$1.53M	0.05%	59
2015 Q1	–	Sell	-39,780	Closed	-$842K	–	261
2014 Q4	$842K	Sell	39,780 -2,800	-7%	-$62.5K	0.2%	78
2014 Q3	$1.01M	Sell	42,580 -1,220	-3%	-$28.1K	0.17%	66
2014 Q2	$1.01M	Hold	43,800	–	–	0.14%	94
2014 Q1	$1.01M	Sell	43,800 -1,450	-3%	-$30.9K	0.17%	77
2013 Q4	$836K	Hold	45,250	–	–	0.11%	96
2013 Q3	$766K	Buy	+45,250	New	+$761K	0.12%	99

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Hirtle Callaghan & Co's NVO Position: Q2 2026 in Review

Hirtle Callaghan & Co sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 19,457 shares — an estimated $715K sold.

Hirtle Callaghan & Co first reported a position in NVO in Q3 2013 and held it in 11 quarters. The position peaked at $1.34M in Q2 2025. 1,352 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Hirtle Callaghan & Co reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
Hirtle Callaghan & Co sold 19,457 Novo Nordisk shares in Q2 2026, an estimated $715K.
Hirtle Callaghan & Co first reported a position in Novo Nordisk in Q3 2013 and held it in 11 quarters.
Hirtle Callaghan & Co's Novo Nordisk position peaked at $1.34M in Q2 2025.
1,352 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Hirtle Callaghan & Co's 13F filing for Q2 2026, filed 14 Aug 2026.